Immune X
Dietary Supplement500 mg Immune X daily as capsules for 16 weeks.
NCT Number: NCT07787130
The goal of this clinical trial is to learn if Immune X can help prevent common cold events in healthy adults who have a history of upper respiratory tract infections. The main questions it aims to answer are:
* Does Immune X reduce the proportion of participants who experience at least one clinically confirmed common cold event during the study period? * Does Immune X affect the number, duration, and severity of common cold events?
Researchers will compare Immune X to a placebo (a look-alike capsule containing inactive ingredients) to see if Immune X helps prevent common cold events.
Participants will:
* Take Immune X or placebo daily for 16 weeks during the winter season. * Attend study visits at the beginning and end of the study and complete questionnaires and symptom assessments throughout the study. * Record cold symptoms, medications, and other study information using a smartphone application. * Provide blood and stool samples during the study.
Trial opening soon.
Get Notified18 year–65 year
All sexes
Interventional
Not applicable
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
500 mg Immune X daily as capsules for 16 weeks.
Matching placebo capsules daily for 16 weeks.
Time frame: Week 2 to Week 16
Proportion of participants with at least one clinically confirmed cold event.
Time frame: Week 2 to Week 16
Mean number of clinically confirmed cold events per participant.
Time frame: Week 2 to Week 16
Duration of clinically confirmed cold events measured in days.
Time frame: Week 2 to Week 16
Wisconsin Upper Respiratory Symptom Survey (WURSS-24): Zero is equivalent to no symptoms and 7 indicates severe.
Time frame: Week 2 to Week 16
Jackson Cold Scale: 0 is equivalent to absent symptoms and 3 indicates severe symptoms
Time frame: Week 2 to Week 16
Wisconsin Upper Respiratory Symptom Survey (WURSS-24) quality-of-life score: Zero is equivalent to no interference and 7 indicates severe interference.
Time frame: Week 2 to Week 16
Number of days from Day 15 after randomization to the first clinically confirmed cold event.
Time frame: Baseline, Weeks 4, 8, 12, and 16
Chalder Fatigue Questionnaire (CFQ-11) total score: 0 is equivalent to less/better than usual and 33 indicates much more/much worse than usual.
Time frame: Week 2 to Week 16
Number of doses and duration of rescue medication use during cold events.
Time frame: Week 2 to Week 16
Mean number of clinically confirmed and unconfirmed cold events per participant.
Time frame: Baseline through Week 16
Number of participants with adverse events.
Contact information is provided by the study sponsor or research team.
Katja A. Schönenberger, PhD
CONTACT
Linda Lopez, PhD
CONTACT
Givaudan France Naturals
Industry
The Effect of Immune X on the Incidence of the Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
Acronym: CELFI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07625683
Acute Cough, Common Cold
Multiple Locations, France
View Trial DetailsNCT07257224
Airway Obstruction, Allergic Rhinitis
Alicante, Spain
View Trial DetailsNCT00448981
Common Cold, Infections
New York, United States
View Trial DetailsNCT05819190
Common Cold, Infections
Sofia, Bulgaria
View Trial Details